OR WAIT null SECS
May 18, 2023
Sania Therapeutics has emerged from stealth mode and launched its technology platforms for enabling the development of novel therapeutics to treat neural circuit dysfunction.
The UK and Switzerland are negotiating a modern free trade agreement.
UK’s NICE has recommended Kapruvia as a treatment for adult patients with moderate-to-severe chronic kidney disease (CKD)-associated pruritus.
UK's NICE has recommended RINVOQ (upadacitinib) as a treatment option for adult patients in England and Wales with moderately to severely active Crohn’s disease.
May 17, 2023
The agency’s safety committee is reviewing hydroxyprogesterone medicines and issuing a reminder on safety issues regarding fluoroquinolone antibiotics.
The agency has published guidance on good practices for securing the supply of medicines.
The report outlines highlights from the agency’s medicines evaluations and milestones for 2022.
May 11, 2023
EC has granted marketing authorization to Chiesi Global Rare Diseases and Protalix BioTherapeutics for PRX-102 (pegunigalsidase alfa).
Critical raw materials supplier, Biosynth, has acquired UK-based Cambridge Research Biochemicals (CRB).
Vetter is further expanding its production capacity and services at its Rankweil, Austria site.